Drug Trial Radar · NCT06148389
The Safety and Tolerability of STSA-1301 Subcutaneous Injection in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Aug 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
Nov 16, 2023
Primary completion
Apr 3, 2024
Study completion Apr 3, 2024
Sponsor
- Lead sponsor
- Staidson (Beijing) Biopharmaceuticals Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Nov 28, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A randomized, double-blind, placebo-controlled, single-ascending dose, phase Ia study to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamics, and immunogenicity of STSA-1301 Subcutaneous Injection in healthy subjects.
Conditions
- Primary Immune Thrombocytopenia
Interventions
STSA-1301 subcutaneous injectionDrug
Subjects will receive the administration dose on Day 0 following protocol requirements.
PlaceboDrug
Subjects will receive the administration dose on Day 0 following protocol requirements.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of treatment-related adverse events as assessed by CTCAE 5.0.Time frame: 50 days
- Safety as measured by subject incidence of treatment-emergent clinically significant changes in clinical laboratory safety tests.Time frame: 50 days
- Safety as measured by subject incidence of treatment-emergent clinically significant changes in vital signs.Time frame: 50 days
- Safety as measured by subject incidence of treatment-emergent clinically significant changes in physical examination.Time frame: 50 days
- Safety as measured by subject incidence of treatment-emergent clinically significant changes in Electrocardiogram (ECG).Time frame: 50 days
- Maximum plasma concentration (Cmax)Time frame: Pre-dose; after dose 2 hours, 4 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 14 days, 21 days and 28 days
- Area under the plasma concentration-time curve from time 0 to the collection time point t of the last measurable concentration (AUC0-t)Time frame: Pre-dose; after dose 2 hours, 4 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 14 days, 21 days and 28 days
- Area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞)Time frame: Pre-dose; after dose 2 hours, 4 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 14 days, 21 days and 28 days
- Time of maximum concentration (Tmax)Time frame: Pre-dose; after dose 2 hours, 4 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 14 days, 21 days and 28 days
- Elimination half-life (t1/2)Time frame: Pre-dose; after dose 2 hours, 4 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 14 days, 21 days and 28 days
- Elimination rate constant of plasma drug concentration in terminal phase (λz)Time frame: Pre-dose; after dose 2 hours, 4 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 14 days, 21 days and 28 days
- Last measurable concentration (Clast)Time frame: Pre-dose; after dose 2 hours, 4 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 14 days, 21 days and 28 days
- Mean residence time (MRT)Time frame: Pre-dose; after dose 2 hours, 4 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 14 days, 21 days and 28 days
- Clearance (CL)Time frame: Pre-dose; after dose 2 hours, 4 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 14 days, 21 days and 28 days
- Apparent volume of distribution (Vz)Time frame: Pre-dose; after dose 2 hours, 4 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 14 days, 21 days and 28 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Ditan Hospital,Capital Medical University
Beijing, Chaoyang District, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.